Psychiatric co-morbidity and substance use disorders: treatment in parallel systems or in one integrated system?
Psychiatric co-morbidity among substance users refers to the simultaneous presence of at least another psychiatric disorder in a person diagnosed with a substance use disorder. Co-morbid patients represent a substantial number of people in treatment and present greater disorder severity from both the clinical and social perspectives than those people diagnosed with only one type of disorder. We present an overview of the current state of the art concerning the choice of site of treatment, the kind of intervention, the length of such treatment, and future goals, aiming to establish a more effective intervention, and finally so as to further improve clinical outcomes.
Institut de Neuropsiquiatria i Addicions, Hospital del Mar-IMIM, Parc de Salut Mar, Passeig Marítim 25–29, Barcelona, Spain. mtorrens@parcdesalutmar.cat
Marta
M
Torrens
Paola C
PC
Rossi
Roser
R
Martinez-Riera
Diana
D
Martinez-Sanvisens
Antoni
A
Bulbena
D001008:Anxiety Disorders / Q000453:epidemiology / Q000628:therapy; D001289:Attention Deficit Disorder with Hyperactivity / Q000453:epidemiology / Q000628:therapy; D015897:Comorbidity; D019033:Delivery of Health Care, Integrated; D003866:Depressive Disorder / Q000453:epidemiology / Q000628:therapy; D017831:Diagnosis, Dual (Psychiatry); D006801:Humans; D008605:Mental Health Services; D011618:Psychotic Disorders / Q000453:epidemiology / Q000628:therapy; D019966:Substance-Related Disorders / Q000453:epidemiology / Q000628:therapy*; D016896:Treatment Outcome